Advances in the prevention of Alzheimer's Disease
Open Access
- 12 May 2015
- journal article
- review article
- Published by H1 Connect in F1000Prime Reports
- Vol. 7 (50), 50
- https://doi.org/10.12703/p7-50
Abstract
Alzheimer's disease (AD), the leading cause of dementia, has reached epidemic proportions, with major social, medical and economical burdens. With no currently available curative treatments, both the World Health Organization and the G8 Dementia Summit recently identified dementia and AD prevention as a major public health priority. Dementia and AD have a wide range of risk factors (genetic, vascular/metabolic and lifestyle-related), which often co-occur and thus interact with each other. Previous intervention efforts aimed at preventing dementia and AD focused on the management of single risk factors, with relatively modest findings. Also, the effect of risk factors depends on age at exposure, indicating that the timing of preventive interventions needs to be carefully considered. In view of the complex multifactorial nature of AD, as well as its long pre-clinical (asymptomatic) phase, interventions simultaneously targeting multiple risk factors and disease mechanisms at an early stage of the disease are most likely to be effective. Three large European multidomain prevention trials have been launched with the goal of preventing cognitive decline, dementia and AD in older adults with different risk profiles. Pharmacological trials are also shifting towards prevention of Alzheimer dementia, by targeting at-risk individuals prior to the onset of cognitive symptoms. The current review will summarize and discuss the evidence on risk and protective factors from observational studies, ongoing lifestyle-related and pharmacological randomized controlled trials (RCTs), as well as future directions for dementia and AD prevention.This publication has 80 references indexed in Scilit:
- Common psychosocial stressors in middle-aged women related to longstanding distress and increased risk of Alzheimer's disease: a 38-year longitudinal population studyBMJ Open, 2013
- Dominantly Inherited Alzheimer Network: facilitating research and clinical trialsAlzheimer's Research & Therapy, 2013
- Preclinical Alzheimer disease—the challenges aheadNature Reviews Neurology, 2012
- Inflammation in Alzheimer Disease--A Brief Review of the Basic Science and Clinical LiteratureCold Spring Harbor Perspectives in Medicine, 2011
- IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030Diabetes Research and Clinical Practice, 2011
- Anti-Aβ Therapeutics in Alzheimer's Disease: The Need for a Paradigm ShiftNeuron, 2011
- A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer diseaseNeurology, 2009
- Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's diseaseProceedings of the National Academy of Sciences of the United States of America, 2009
- Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trialThe Lancet Neurology, 2008
- Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset FamiliesScience, 1993